Edition:
United Kingdom

Arcturus Therapeutics Ltd (ARCT.OQ)

ARCT.OQ on NASDAQ Stock Exchange Global Market

8.59USD
4:00pm GMT
Change (% chg)

$0.08 (+0.94%)
Prev Close
$8.51
Open
$8.61
Day's High
$8.61
Day's Low
$8.55
Volume
535
Avg. Vol
25,111
52-wk High
$17.99
52-wk Low
$5.81

Latest Key Developments (Source: Significant Developments)

Alcobra qtrly ‍net loss per share $0.09​
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Alcobra Ltd :Alcobra announces third quarter 2017 financial results and provides corporate update.Alcobra Ltd - qtrly ‍net loss per share $0.09​.  Full Article

ARCTURUS, SYNTHETIC GENOMICS ANNOUNCE ALLIANCE TO DEVELOP VACCINES, THERAPEUTICS
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Synthetic Genomics::ARCTURUS THERAPEUTICS AND SYNTHETIC GENOMICS ANNOUNCE STRATEGIC ALLIANCE TO DEVELOP NEXT-GENERATION VACCINES AND THERAPEUTICS.UNDER COLLABORATION, CO WILL HAVE EXCLUSIVE ACCESS TO LUNAR TECHNOLOGY FOR VACCINES AND THERAPEUTICS, USING SELF-AMPLIFYING RNA​.UNDER, COLLABORATION, ‍ARCTURUS WILL RECEIVE UPFRONT CASH PAYMENT, RESEARCH AND DEVELOPMENT SUPPORT, PRE-CLINICAL, DEVELOPMENT, SALES MILESTONE PAYMENTS.‍UNDER COLLABORATION, ARCTURUS WILL ALSO RECEIVE ROYALTY PAYMENTS ON ANY FUTURE SUBLICENSED PRODUCTS ​.  Full Article

Alcobr, Arcturus Therapeutics agree to merge
Wednesday, 27 Sep 2017 

Sept 27 (Reuters) - Alcobra Ltd ::Alcobra ltd and Arcturus therapeutics, inc. Agree to merge.Proposed merger has been unanimously approved by boards of directors of both companies.Co, Arcturus therapeutics​ ‍sign definitive agreement to merge two companies in an all-stock transaction.Holders of arcturus outstanding capital stock immediately prior to merger will receive ordinary shares of alcobra in merger​.Conversion ratio for deal is based on a valuation of co of $46.7 million, including about $35 million of expected alcobra cash at closing​.Combined company well-capitalized with approximately $40 million in cash projected at closing.Joseph E. Payne is expected to serve as president and chief executive officer of combined company​.On pro forma basis for combined co,alcobra shareholders to own about 40%,arcturus shareholders expected to own about 60% of combined co.Board of directors of combined company will be comprised of seven members​.$40 million in cash projected at closing is expected to fund co through multiple value creation milestones and into early clinical development.Seven members will include three members to be designated by Alcobra and four members to be designated by Arcturus​.  Full Article

Alcobra reports Q4 loss per share $0.22
Wednesday, 15 Feb 2017 

Alcobra Ltd : Alcobra announces fourth-quarter and full-year 2016 financial results and provides corporate update . Qtrly loss per share $0.22 . Alcobra ltd - qtrly loss per share $0.22 .Q4 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S.  Full Article

Alcobra reports Q2 loss per share of $0.21
Tuesday, 30 Aug 2016 

Alcobra Ltd : Alcobra announces second quarter 2016 financial results and provides corporate update .Qtrly loss per share $0.21.  Full Article

Alcobra grants European orphan drug designation for Metadoxine
Tuesday, 19 Jul 2016 

Alcobra Ltd : Alcobra granted European orphan drug designation for Metadoxine in fragile X syndrome .European commission has granted orphan drug designation to Metadoxine for treatment of fragile X syndrome within European Union.  Full Article

Alcobra qtrly loss per share $0.18
Monday, 16 May 2016 

Alcobra Ltd : Qtrly loss per share $ 0.18 . Q1 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S .Alcobra announces first quarter 2016 financial results and provides corporate update.  Full Article